Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride
  • Combined Modality Therapy
  • Cytarabine / therapeutic use
  • Drug Resistance, Neoplasm*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Melphalan / therapeutic use
  • Nitrogen Mustard Compounds / therapeutic use
  • Transplantation, Autologous

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Nitrogen Mustard Compounds
  • Cytarabine
  • Bendamustine Hydrochloride
  • Melphalan